PLoS ONE (Jan 2023)

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo

  • Trésor Zola Matuvanga,
  • Joachim Mariën,
  • Ynke Larivière,
  • Bernard Isekah Osang’ir,
  • Solange Milolo,
  • Rachel Meta,
  • Emmanuel Esanga,
  • Vivi Maketa,
  • Junior Matangila,
  • Patrick Mitashi,
  • Steve Ahuka Mundeke,
  • Hypolite Muhindo-Mavoko,
  • Jean-Jacques Muyembe Tamfum,
  • Pierre Van Damme,
  • Jean-Pierre Van Geertruyden

Journal volume & issue
Vol. 18, no. 9

Abstract

Read online

Introduction A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. Methods Serum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. Results The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7–2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0–1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5–10.9) samples using FANG ELISA. Conclusion In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.